Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM

Immune checkpoint inhibitors have become major therapeutic agents in oncology over the last few years. However, they are associated with a variety of potentially severe autoimmune phenomena. We present a patient with advanced adenocarcinoma of the lung, who presented with acute liver injury two week...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzadok, Roie, Levy, Sharon, Aouizerate, Jessie, Shibolet, Oren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967548/
https://www.ncbi.nlm.nih.gov/pubmed/35368450
http://dx.doi.org/10.1155/2022/5090200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967548/
https://www.ncbi.nlm.nih.gov/pubmed/35368450
http://dx.doi.org/10.1155/2022/5090200

Ejemplares similares